Driven by innovation and quality, through global accreditation, IDT Australia (ASX: IDT) delivers end-to-end cGMP CDMO solutions – from active pharmaceutical ingredients to finished dosage forms. Our integrated R&D, formulation, and cGMP manufacturing expertise enables seamless development of oral and injectable medicines for partners worldwide.
From API development to finished dose forms, we support every stage – from pre-clinical research through to commercial production.
Our manufacturing standards meet the highest international benchmarks, ensuring reliability and safety.
Tailored solutions designed to meet your unique project requirements and specifications for every stage.
Our expert team combines advanced technical skills with industry experience to deliver outstanding results
Australia is a global hub for high-quality, cost-efficient pharmaceutical manufacturing – combining scientific excellence, rapid study start-up, and a trusted clinical trial ecosystem.
With the R&D Tax Incentive offering up to a 43.5% refundable cash benefit for eligible projects, partnering with IDT Australia helps you accelerate development while maximising your R&D investment.
From lab to first-patient-in, Australia’s streamlined regulatory pathways mean your drug can move through development and into clinical trials faster – and with confidence.
Learn More
Real feedback from those who trust us to deliver every step of the way
Working with IDT Australia has been instrumental in advancing our pharmaceutical projects and securing continuity of supply. Their deep expertise in analytical method transfer, API, process validation, regulatory support and manufacturing Drug Substance and Drug Product has been highly valuable, ensuring the seamless integration of complex processes.… They have shown great professionalism and reliability throughout the collaboration, consistently meeting deadlines and maintaining high quality standards.
Read More
We have collaborated with IDT Australia to advance our novel antioxidant therapies for treatment of ocular, metabolic and neurological diseases and conditions. Their end-to-end expertise from producing API to finished dosage form and integrated services is particularly attractive. Working with IDT Australia has significantly enhanced our ability to advance investigational medicinal products through clinical trials effectively and efficiently. We highly recommend IDT’s CDMO services for their technical expertise, regulatory knowledge, and commitment to quality.
Read MoreDiscover how our end-to-end services can support your drug development journey
Talk to an expert